1. Specifications table {#s0005}
=======================

TableSubject area*Biology*More specific subject areaProtein synthesis inhibition of cancer cells *in vitro*Mechanism of action of potential anticancer drugType of data*Graphs and table*How data was acquired*Flow cytometer, microplate reader, search on databases*Data format*Analyzed graphs and raw data retrieval (table)*Experimental factors*As in the description of the data and materials and methods*Experimental features*As in the description of the data and materials and methods*Data source location*Lab. de Cancérologie et Toxicologie Experimentale, Université Libre de Bruxelles, Brussels, Belgium.Life Technologies,* Madison, USAData accessibility*Data is with this article*

2. Value of the data {#s0010}
====================

•This data offers an extended comprehension of CM16 mechanism of action as a protein synthesis inhibitor in cancer cells.•Assays performed to evaluate transcription and translation initiation provide valuable data and may be used as tools in other cell-based investigations of potential protein synthesis inhibitors.•The data presented shows that different methods add to and enrich the investigation of the mechanism of action of proteins synthesis inhibitors in cancer cells. Therefore, these approaches might be useful in similar studies.

3. Data {#s0015}
=======

Firstly, data on CM16-induced cytostatic effects is presented. As shown in [@bib1] CM16 displays cytostatic effects at its IC~50~ in glioma Hs683, melanoma SKMEL-28 and breast adenocarcinoma MDA-MB-231 cells. Thus, CM16 effect on the cell cycle of both glioma Hs683 ([Fig. 1](#f0005){ref-type="fig"}A) cells and SKMEL-28 ([Fig. 1](#f0005){ref-type="fig"}B) are presented. After data showing CM16 inhibiting translation [@bib1], further investigation on the effects of CM16 on newly synthesized mRNA (transcription) were carried out and generated the data here shown ([Fig. 2](#f0010){ref-type="fig"}A-B). CM16 effects on PERK activity, is shown in [Fig. 3](#f0015){ref-type="fig"}. The data on [Table 1](#t0005){ref-type="table"} refers to the genes related to translation that were analyzed for their transcriptomic expression in the cell lines most and least sensitive to CM16 effects, according to the NCI 60-cell-line growth inhibitory evaluation [@bib1].Fig. 1Cell cycle effects of CM16 on A: Hs683 at 0.1 µM; and B: SKMEL-28 at 0.5 µM. Data are expressed as the mean percentage of cells in each phase of the cell cycle of four replicates. As proliferation inhibition were observed on the three cancer models under study at their GI~50~ and the lack of evidence of any effects of CM16 on the cell cycle of Hs683 and SKMEL-28, we did not perform the cell cycle analysis on MDAMB-231.Fig. 1Fig. 2Effects of CM16 on newly synthesized mRNA in A: Hs683 and B: SKMEL-28 cell lines. Results are expressed as the mean neosynthesized RNA amounts normalized to the control (100%) ± S.E.M. of six replicates. No significant effects were observed for up to 24 h in the presence of 5.0 µM CM16 in those two cell lines, thus we did not further assayed the breast cancer cell line MDA-MB-231.Fig. 2Fig. 3PERK kinase activity *in vitro* in the presence or absence of CM16.Fig. 3Table 1List of genes analyzed for the transcript intensity from the NCI cell line panel.Table 1ProteinProtein code (UniProt)Gene (HGNC Symbol)Gene code (Entrez Gene)Eukaryotic translation initiation factor 2 subunit 1[P05198](ncbi-p:P05198){#ir0005}EIF2S11965Eukaryotic translation initiation factor 2 subunit 2[P20042](ncbi-p:P20042){#ir0010}EIF2S28894Eukaryotic translation initiation factor 2 subunit 3[P41091](ncbi-p:P41091){#ir0015}EIF2S31968Translation initiation factor eIF-2B subunit alpha[Q14232](ncbi-p:Q14232){#ir0020}EIF2B11967Translation initiation factor eIF-2B subunit beta[P49770](ncbi-p:P49770){#ir0025}EIF2B28892Translation initiation factor eIF-2B subunit gamma[Q9NR50](ncbi-p:Q9NR50){#ir0030}EIF2B38891Translation initiation factor eIF-2B subunit delta[Q9UI10](ncbi-p:Q9UI10){#ir0035}EIF2B48890Translation initiation factor eIF-2B subunit epsilon[Q13144](ncbi-p:Q13144){#ir0040}EIF2B58893Eukaryotic translation initiation factor 4E[P06730](ncbi-p:P06730){#ir0045}EIF4E1977Eukaryotic translation initiation factor 4E-binding protein 1[Q13541](ncbi-p:Q13541){#ir0050}EIF4EBP11978Eukaryotic translation initiation factor 4 gamma 1[Q04637](ncbi-p:Q04637){#ir0055}EIF4G11981Eukaryotic translation initiation factor 4 gamma 2[P78344](ncbi-p:P78344){#ir0060}EIF4G21982Eukaryotic translation initiation factor 4 gamma 3[O43432](ncbi-p:O43432){#ir0065}EIF4G38672MAP kinase-interacting serine/threonine-protein kinase 1[Q9BUB5](ncbi-p:Q9BUB5){#ir0070}MKNK18569MAP kinase-interacting serine/threonine-protein kinase 2[Q9HBH9](ncbi-p:Q9HBH9){#ir0075}MKNK22872Eukaryotic initiation factor 4A-I[P60842](ncbi-p:P60842){#ir0080}EIF4A11973Eukaryotic initiation factor 4A-II[Q14240](ncbi-p:Q14240){#ir0085}EIF4A21974Eukaryotic initiation factor 4A-III[P38919](ncbi-p:P38919){#ir0090}EIF4A39775Programmed cell death protein 4[Q53EL6](ncbi-p:Q53EL6){#ir0095}PDCD427250Eukaryotic translation initiation factor 5A-1[P63241](ncbi-p:P63241){#ir0100}EIF5A1984Eukaryotic translation initiation factor 5A-2[Q9GZV4](ncbi-p:Q9GZV4){#ir0105}EIF5A256648Eukaryotic translation initiation factor 5B[O60841](ncbi-p:O60841){#ir0110}EIF5B9669Eukaryotic translation initiation factor 6[P56537](ncbi-p:P56537){#ir0115}EIF63692Eukaryotic translation initiation factor 1[P41567](ncbi-p:P41567){#ir0120}EIF110209Eukaryotic translation initiation factor 1A, X-chromosomal[P47813](ncbi-p:P47813){#ir0125}EIF1AX1964Eukaryotic translation initiation factor 1A, Y-chromosomal[O14602](ncbi-p:O14602){#ir0130}EIF1AY9086Probable RNA-binding protein EIF1AD[Q8N9N8](ncbi-p:Q8N9N8){#ir0135}EIF1AD84285Eukaryotic translation initiation factor 3 subunit A[Q14152](ncbi-p:Q14152){#ir0140}EIF3A8661Eukaryotic translation initiation factor 3 subunit B[P55884](ncbi-p:P55884){#ir0145}EIF3B8662Eukaryotic translation initiation factor 3 subunit H[O15372](ncbi-p:O15372){#ir0150}EIF3H8667Eukaryotic translation initiation factor 3 subunit I[Q13347](ncbi-p:Q13347){#ir0155}EIF3I8668Eukaryotic translation initiation factor 3 subunit M[Q7L2H7](ncbi-p:Q7L2H7){#ir0160}EIF3M10480Eukaryotic translation initiation factor 3 subunit E[P60228](ncbi-p:P60228){#ir0165}EIF3E3646Eukaryotic translation initiation factor 3 subunit F[O00303](ncbi-p:O00303){#ir0170}EIF3F8665Eukaryotic translation initiation factor 2-alpha kinase 3[Q9NZJ5](ncbi-p:Q9NZJ5){#ir0175}EIF2AK39451Eukaryotic translation initiation factor 2-alpha kinase 4[Q9P2K8](ncbi-p:Q9P2K8){#ir0180}EIF2AK4440275Interferon-induced, double-stranded RNA-activated protein kinase[P19525](ncbi-p:P19525){#ir0185}EIF2AK25610Eukaryotic translation initiation factor 2-alpha kinase 1[Q9BQI3](ncbi-p:Q9BQI3){#ir0190}EIF2AK127102Elongation factor 1-alpha 1[P68104](ncbi-p:P68104){#ir0195}EEF1A11915Elongation factor 2[P13639](ncbi-p:P13639){#ir0200}EEF21938Serine/threonine-protein kinase mTOR[P42345](ncbi-p:P42345){#ir0205}MTOR2475RAC-alpha serine/threonine-protein kinase[P31749](ncbi-p:P31749){#ir0210}AKT1207RAC-beta serine/threonine-protein kinase[P31751](ncbi-p:P31751){#ir0215}AKT2208RAC-gamma serine/threonine-protein kinase[Q9Y243](ncbi-p:Q9Y243){#ir0220}AKT310000Ribosomal protein S6 kinase beta-1[P23443](ncbi-p:P23443){#ir0225}RPS6KB16198Ribosomal protein S6 kinase beta-2[Q9UBS0](ncbi-p:Q9UBS0){#ir0230}RPS6KB26199Myc proto-oncogene protein[P01106](ncbi-p:P01106){#ir0235}MYC4609Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform[P42336](ncbi-p:P42336){#ir0240}PIK3CA5290Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN[P60484](ncbi-p:P60484){#ir0245}PTEN5728Hamartin[Q92574](ncbi-p:Q92574){#ir0250}TSC17248Tuberin[P49815](ncbi-p:P49815){#ir0255}TSC27249Cellular tumor antigen p53[P04637](ncbi-p:P04637){#ir0260}TP537157Retinoblastoma-associated protein[P06400](ncbi-p:P06400){#ir0265}RB159253-phosphoinositide-dependent protein kinase 1[O15530](ncbi-p:O15530){#ir0270}PDPK15170Mitogen-activated protein kinase 1[P28482](ncbi-p:P28482){#ir0275}MAPK15594Vascular endothelial growth factor A[P15692](ncbi-p:P15692){#ir0280}VEGFA774278 kDa glucose-regulated protein[P11021](ncbi-p:P11021){#ir0285}HSPA53309[^1]

4. Experimental design, materials and methods {#s0020}
=============================================

4.1. Cell lines and compound {#s0025}
----------------------------

The human cancer cell lines, oligodendroglioma Hs683 (ATCC code HTB-138) and melanoma SKMEL-28 (ATCC code HTB-72) were herein used. Cells were cultivated at 37 °C with 5% CO~2~ in RPMI culture medium supplemented with 10% FBS, 200U penicillin--streptomycin, 0.1 mg/ml gentamicin and 4 mM L-glutamine. CM16 was synthetized as previously described [@bib2] and the experiments were designed with the cell lines described above treated with different concentrations of CM16, based on its IC~50~.

4.2. Analysis of CM16 effects on cell cycle {#s0030}
-------------------------------------------

Cell cycle analysis was performed with flow cytometry through the measurements of DNA content with propidium iodide. Hs683 and SKMEL-28 were seeded in cell culture flasks and left untreated or treated with CM16 at its respective IC~50~ in each cell line for 24 h, 48 h and 72 h. The samples were then centrifuged (10 min, 1500 rcf, 4 °C), resuspended in PBS and pellets were resuspended in cold ethanol 70% for fixation. Staining with 0.08 mg/ml propidium iodide solution (0.08 mg/ml PI; 0.2 mg/ml RNAse in PBS) followed after a PBS wash. The samples were incubated at 37 °C for 30 min and stored at 4 °C for a few hours. Analysis was performed with the Cell Lab Quanta (Beckman Coulter, Analis, Suarlée, Belgium). The experiment was performed once in quadruplicate.

4.3. Analysis of CM16 effects on transcription {#s0035}
----------------------------------------------

Neosynthesized RNA was evaluated through incorporation of a nucleoside analog, 5-ethynyl-uridine, using the Click iT-RNA HCS (Invitrogen, Life Technologies, Merelbeke, Belgium). The alkyne-containing nucleosides react with a fluorescent dye containing the azide moiety after their incorporation into cellular RNA. Briefly, Hs683 or SKMEL-28 cells were seeded and after attachment they were either left untreated (negative control) or treated with CM16 or the positive control actinomycin (Life Technologies, Paisley, UK). After the treatment with the analog 5-ethynyl uridine (4 mM) for two h, the cells were fixed, stained (Alexa Fluor 488 and 594) and fluorescence readings (ex/em: 495/520 nm) were carried out in microplate reader (SynergyMX Biotek, Winooski, USA: ex/em: 350/460 nm). Normalization according to cell number was carried out as described in the user manual with Hoescht counterstaining. The experiment was performed once in sextuplicate.

4.4. PERK inhibition {#s0040}
--------------------

PERK activity was evaluated by the Life Technologies screening service (Lantha Screen, Madison, USA). The *in vitro* assay used is based on FRET between a terbium-labeled antibody and the phosphorylated product of the active kinase: TR-FRET increases proportionally to their binding and thereby to the quantity of the phosphorylated product. CM16 compound at different concentrations or the control solutions were mixed with the kinase/substrate/ATP mixture into the wells. After 60 min of reaction at room temperature, the detection mix was added and left to equilibrate for an h prior to fluorescence reading.
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[^1]: Data retrieved from: www.proteinatlas.com; www.uniprot.org; www.genenames.org and [http://www.ncbi.nlm.nih.gov/gene in](http://www.ncbi.nlm.nih.gov/gene%20in){#ir0290} September 2015.
